Additionally, in almost all clinical trial, roxadustat treatment was observed to reduce serum hepcidin levels in patients with NDD-CKD and DD-CKD, indicating that roxadustat may help to ameliorate ESA hyporesponsiveness induced by functional iron deficiency. Here, HAMP is linked to chronic kidney disease.